Double-Drug attack: new hope for tough Crohn's cases?
NCT ID NCT06520397
First seen Mar 24, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study is for adults with Crohn's disease who did not get enough help from the standard dose of a drug called ustekinumab. It compares two approaches: adding another drug (upadacitinib) to ustekinumab, versus increasing the dose of ustekinumab alone. The goal is to see which strategy better reduces gut inflammation and improves symptoms, while checking for side effects. About 214 participants will be randomly assigned to one of the two treatment groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wei Wang
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.